Market Overview

XenoPort May Be Beneficiary of Biogen Patent Filings

Share:
Related BIIB
Schoenebaum: Biotech P/Es Show 'Buying Signal' With Caveat; Amgen, Biogen, Celgene & Gilead Have Catalysts
Leerink Is Back On Board The Biotech Train
Former Leaders Show Up On New Low List; D.R. Horton Sinks Again (Investor's Business Daily)
Related XNPT
XenoPort Continues Higher Amid Takeover Rumors
9 Stocks Moving In Friday's Pre-Market Session

Brian Abrahams, a Wells Fargo analyst, believes that Biogen (NASDAQ: BIIB) MS pill patents will be a positive boost for XenoPort (NASDAQ: XNPT).

Further patent applications could provide patent protection until 2032 for Biogen's BG-12, which should benefit XenoPort's '829 drug, an earlier stage derivative of BG-12, with added protection from generic competition.

BIIB is currently up 1.5 percent in pre-market trading, while XNPT is currently unchanged.

Latest Ratings for BIIB

DateFirmActionFromTo
Feb 2016Leerink SwannInitiates Coverage onMarket Perform
Jan 2016JefferiesMaintainsBuy
Jan 2016Credit SuisseInitiates Coverage onNeutral

View More Analyst Ratings for BIIB
View the Latest Analyst Ratings

Posted-In: Analyst Color News FDA Analyst Ratings

 

Related Articles (BIIB + XNPT)

View Comments and Join the Discussion!

Get Benzinga's Newsletters